Trident Texofab Intrinsic Value
TTFL Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹74.89 | ₹59.91 - ₹89.87 | -70.0% | EPS: ₹2.30, Sector P/E: 12x |
| Book Value Method | asset | ₹49.93 | ₹44.94 - ₹54.92 | -80.0% | Book Value/Share: ₹33.57, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹74.89 | ₹67.40 - ₹82.38 | -70.0% | Revenue/Share: ₹92.86, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹99.86 | ₹89.87 - ₹109.85 | -60.0% | EBITDA: ₹9.00Cr, EV/EBITDA: 6x |
| Simple DCF (5Y) | dcf | ₹99.86 | ₹79.89 - ₹119.83 | -60.0% | CF Growth: 14.5%, Discount: 15% |
| PEG Ratio Method | growth | ₹74.89 | ₹67.40 - ₹82.38 | -70.0% | EPS Growth: 20.0%, Fair P/E: 16.0x |
| Growth Adjusted P/E | growth | ₹74.89 | ₹67.40 - ₹82.38 | -70.0% | Revenue Growth: 11.2%, Adj P/E: 8.4x |
| ROE Based Valuation | profitability | ₹124.83 | ₹112.35 - ₹137.31 | -50.0% | ROE: 6.4%, P/E Multiple: 10x |
| Graham Defensive Method | conservative | ₹74.89 | ₹67.40 - ₹82.38 | -70.0% | EPS: ₹2.30, BVPS: ₹33.57 |
Want to compare with current market value? Check TTFL share price latest .
Valuation Comparison Chart
TTFL Intrinsic Value Analysis
What is the intrinsic value of TTFL?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Trident Texofab (TTFL) is ₹74.89 (median value). With the current market price of ₹249.65, this represents a -70.0% variance from our estimated fair value.
The valuation range spans from ₹49.93 to ₹124.83, indicating ₹49.93 - ₹124.83.
Is TTFL undervalued or overvalued?
Based on our multi-method analysis, Trident Texofab (TTFL) appears to be trading above calculated value by approximately 70.0%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 5.69 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | 2.15 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Return on Equity | 6.4% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 7.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.29x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
Related Pages for Trident Texofab
Additional stock information and data for TTFL
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹-14 Cr | ₹-24 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹3 Cr | ₹3 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹6 Cr | ₹6 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹1 Cr | ₹-1 Cr | Positive Operating Cash Flow | 6/10 |
| March 2021 | ₹2 Cr | ₹-3 Cr | Positive Operating Cash Flow | 6/10 |